Highlights
==========


**Drug-eluting stents** 

Drug-eluting stents are safer than bare-metal stents in the first year after insertion. However, rates of death and repeat revascularization appear to favour bare-metal stents in years 2 and 3. This is the finding of a 3-year follow-up study based on a large multicentre registry of all patients in the province of Alberta who were given drug-eluting or bare-metal stents during angioplasty. **See Research, page** [167](http://www.cmaj.ca/lookup/volpage/180/167?iss=2)

![Figure1](http://www.cmaj.ca/https://www.cmaj.ca/content/cmaj/180/2/145/F1.medium.gif)

[Figure1](http://www.cmaj.ca/content/180/2/145/F1)

Photo by: Don Farrall/Getty Images

The long-term safety of drug-eluting stents, especially regarding late thrombosis, remains a concern, say Généreux and Mehran. **See Commentary, page** [154](http://www.cmaj.ca/lookup/volpage/180/154?iss=2)

**Hospital at home** 

The “hospital-at-home” model, which is intended to avoid admission to hospital, was associated with a reduction in mortality at 6 months, greater satisfaction with care and lower costs. Shepperd and colleagues report this finding from their systematic review that included a meta-analysis of individual patient data. **See Research, page** [175](http://www.cmaj.ca/lookup/volpage/180/175?iss=2)

The hospital-at-home model could be one element in a portfolio of models for keeping certain patients with an acute illness out of hospital, says Leff. **See Commentary, page** [156](http://www.cmaj.ca/lookup/volpage/180/156?iss=2)

**Safety of aprotinin** 

Aprotinin, which is used to minimize the loss of blood during cardiac surgery, may be associated with a moderate increase in the risk of death when compared to lysine analogues, according to a systematic review by Henry and colleagues. Based on these findings, the authors have modified the conclusion of their previous Cochrane review that was performed before a trial that raised concerns about the safety of aprotinin. **See Research, page** [183](http://www.cmaj.ca/lookup/volpage/180/183?iss=2)

![Figure2](http://www.cmaj.ca/https://www.cmaj.ca/content/cmaj/180/2/145/F2.medium.gif)

[Figure2](http://www.cmaj.ca/content/180/2/145/F2)

Photo by: Photos.com

**Hepatitis B immunization** 

What is the optimal age for hepatitis B vaccination? Mackie and colleagues review the evidence for the effectiveness of vaccination programs for infants and adolescents. **See Analysis, page** [196](http://www.cmaj.ca/lookup/volpage/180/196?iss=2)

**Neurofibromatosis** 

A 75-year-old man with long-standing neurofibromatosis and progressively decreasing vision in his right eye gives readers an opportunity to recall what they know about the condition first described by von Recklinghausen. **See Practice, page** [203](http://www.cmaj.ca/lookup/volpage/180/203?iss=2)

![Figure3](http://www.cmaj.ca/https://www.cmaj.ca/content/cmaj/180/2/145/F3.medium.gif)

[Figure3](http://www.cmaj.ca/content/180/2/145/F3)

**Chromaturia and discoloration of skin** 

A 54-year-old woman rescued from an apartment fire developed bright red discoloration of her skin and urine after being treated with hydroxocobalamin for cyanide poisoning. **See Clinical images, page** [251](http://www.cmaj.ca/lookup/volpage/180/251?iss=2)

![Figure4](http://www.cmaj.ca/https://www.cmaj.ca/content/cmaj/180/2/145/F4.medium.gif)

[Figure4](http://www.cmaj.ca/content/180/2/145/F4)

**European physicians crossing borders** 

Record numbers of European physicians are moving to other countries, raising concerns about patient safety and certification standards. **See News, page** [158](http://www.cmaj.ca/lookup/volpage/180/158?iss=2)